* Cognition Therapeutics Inc CGTX.OQ CGTX.O is expected
to show no change in quarterly revenue when it reports
results on August 8.
*
* Refinitiv's mean analyst estimate for Cognition
Therapeutics
Inc is for a loss of 19 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cognition
Therapeutics Inc is $8, above its last closing price of $1.77.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.18 -0.18 -0.21 Missed -19.8
Dec. 31 2023 -0.05 -0.22 -0.20 Beat 10.9
Sep. 30 2022 -0.34 -0.38 -0.29 Beat 24.5
Jun. 30 2022 -0.29 -0.32 -0.25 Beat 22.2
Mar. -0.29 -0.29 -0.17 Beat 40.7
31 2022
Dec. 31 2021 -0.17 -0.26 -11.74 Missed -4,424
.1
Sep. 30 2021 -0.57 -0.57 -8.12 Missed -1,324
.6
This summary was machine generated August 4 at 18:35 GMT. All
figures in US dollars unless otherwise stated